Expands clinical development of Oral KORSUVA™ into neuropathic pruritus STAMFORD, Conn. , Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by

STAMFORD, Conn. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced

First NDA submission for Company’s lead program, KORSUVA™ Injection – NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection – STAMFORD, Conn. , Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.

- Topline data expected in first half of 2021   - STAMFORD, Conn. , Dec. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting

STAMFORD, Conn. , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today

– Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa

STAMFORD, Conn. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that

- Results from global KALM-2 p ivotal Phase 3 t rial of KORSUVA ™ Injection in h emodialysis p atients with p ruritus to be presented – - NDA submission for KORSUVA Injection   on track for fourth quarter 2020 - STAMFORD, Conn. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:

Vifor Pharma secures commercial rights for IV Korsuva   in non- Fresenius Medical Care   dialysis clinics   representing approx. 66% of the market ,   under a profit - sharing arrangement   with Cara Cara will receive a USD 100 million upfront payment and an equity investment of USD 50 million IV

STAMFORD, Conn. , Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the